Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.

PloS one - 1 Jan 2013

Thompson Cheryl L, Fink Stephen P, Lutterbaugh James D, Elston Robert C, Veigl Martina L, Markowitz Sanford D, Li Li

Abstract excerpt

BACKGROUND: 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a metabolic antagonist of COX-2, catalyzing the degradation of inflammation mediator prostaglandin E2 (PGE2) and other prostanoids. Recent studies have established the 15-PGDH gene as a colon cancer suppressor. METHODS: We evaluated 15-PDGH as a colon cancer susceptibility locus in a three-stage design. We first genotyped 102 single-nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Case-Control Studies
Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Genotype

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 23717544
DOI: 10.1371/journal.pone.0064122
PMCID: PMC3661460

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.PMID 23717544Read ↗

Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk.Semantic proximity Read ↗

Single nucleotide polymorphism rs2555639 in 15-PGDH and colorectal cancer metastasis.Semantic proximity Read ↗

Genetic variability in key genes in prostaglandin E2 pathway (COX-2, HPGD, ABCC4 and SLCO2A1) and their involvement in colorectal cancer development.Semantic proximity Read ↗

Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk.Semantic proximity Read ↗

Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.Semantic proximity Read ↗

Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry.Semantic proximity Read ↗

Repression of 15-Hydroxyprostaglandin Dehydrogenase Involves Histone Deacetylase 2 and Snail in Colorectal CancerSemantic proximity Read ↗

Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk.Semantic proximity Read ↗

Rho GTPase Activating Protein 15 (ARHGAP15) increases cancer risk in patients with diverticular diseaseSemantic proximity Read ↗

Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2/G9a in CholangiocarcinomaSemantic proximity Read ↗

COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.Semantic proximity Read ↗

Association between polymorphisms of TAS2R16 and susceptibility to colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.